ABC | Volume 112, Nº2, February 2019

Original Article Badavi et al Trimetazidine effects on diabetic hearts Arq Bras Cardiol. 2019; 112(2):173-178 1. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213-23. 2. Gohari A, Noorafshan A, Akmali M, Zamani-Garmsiri, Seghatoleslam A. Urtica Dioica Distillate (Aragh Gazaneh) regenerates pancreatic beta cells in streptozotocin-induced diabetic rat. Iran J Med Sci. 2018;43(2):174-83. 3. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748-57. 4. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 2011;48(3):173-81. 5. Cardoso CR, Salles GF, Deccache W. QTc interval prolongation is a predictor of future strokes in patients with type 2 diabetes mellitus. Stroke. 2003;34(9):2187-94. 6. Christensen PK, Gall MA, Major-Pedersen A, Sato A, Rossing P, Breum L, et al. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest. 2000;60(4):323-32. 7. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens. 2001;19(10):1883-91. 8. Tuomainen T, Tavi P. The role of cardiac energy metabolism in cardiac hypertrophy and failure. Exp Cell Res. 2017;360(1):12-8. 9. Rimbaud S, Sanchez H, Garnier A, Fortin D, Bigard X, Veksler V, et al. Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol. 2009;46(6):952-9. 10. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59(10):913-22. 11. Tsioufis K, Andrikopoulos G, Manolis A. Trimetazidine and cardioprotection: facts and perspectives. Angiology. 2015;66(3):204-10. 12. LopatinYM,RosanoGM,FragassoG,LopaschukGD,SeferovicPM,Gowdak LH, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016 Jan 15;203:909-15. 13. Liu X, Gai Y, Liu F, GaoW, Zhang Y, XuM, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res. 2010;88(1):150-8. 14. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003 Nov 28;2:16. 15. OlfertCB,McWilliamAA. .Guidetothecarenduseofexperimentalanimals. 2nd ed. Canada: McWilliam; 1998. 16. Rosner B. Fundamentals of biostatistics. 6th ed. Boston : Brooks/Cole; 2005. 17. Xiang YL, He L, Xiao J, Xia S, Deng SB, Xiu Y, et al. Effect of trimetazidine treatment on the transient outward potassium current of the left ventricular myocytes of rats with streptozotocin-induced type 1 diabetes mellitus. Braz J Med Biol Res. 2012;45(3):205-11. 18. Gargouri M, Magne C, El Feki A. Hyperglycemia, oxidative stress, liver damage and dysfunction in alloxan-induced diabetic rat are prevented by Spirulina supplementation. Nutr Res. 2016;36(11):1255-68. 19. JoukarS,Ghasemipour-AfsharE,SheibaniM,NaghshN,BashiriA.Protective effects of saffron (Crocus sativus) against lethal ventricular arrhythmias induced by heart reperfusion in rat: a potential anti-arrhythmic agent. Pharm Biol. 2013;51(7):836-43. 20. Joukar S, Zarisfi Z, Sepehri G, Bashiri A. Efficacy of Melissa officinalis in suppressing ventricular arrhythmias following ischemia-reperfusion of the heart: a comparisonwith amiodarone. Med Princ Pract. 2014;23(4):340-5. 21. Radmanesh E, Dianat M, Badavi M, Goudarzi G, Mard SA. The cardioprotective effect of vanillic acid on hemodynamic parameters, malondialdehyde, and infarct size in ischemia-reperfusion isolated rat heart exposed to PM10. Iran J Basic Med Sci. 2017;20(7):760-8. 22. Dorri Mashhadi F, Zavvar Reza J, Jamhiri M, Hafizi Z, ZareMehrjardi F, Safari F. TheeffectofresveratrolonangiotensinII levelsandtherateoftranscriptionofits receptorsintheratcardiachypertrophymodel.JPhysiolSci.2017;67(2):303-9. 23. Casis O, Echevarria E. Diabetic cardiomyopathy: electromechanical cellular alterations. Curr Vasc Pharmacol. 2004;2(3):237-48. 24. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology. 2002;98(1-2):33-9. 25. Suner A, Cetin M. The effect of trimetazidine on ventricular repolarization indexes and left ventricular diastolic function in patients with coronary slow flow. Coron Artery Dis. 2016;27(5):398-404. 26. Balenovic D, Prkacin I, Cavric G, Horvat I, Pocanic D, Baotic I. [The effects of trimetazidine on QT-interval prolongation in patients with chronic kidney diseasestage III-IV (predialysisCRD)].ActaMedCroatica.2012;66(3):153-6. References Author contributions Design and conception of the study: Ramezani-Aliakbari F, Badavi M; Acquisition of data: Dianat M, Mard SA, Ahangarpour A; Analysis and interpretation of the data: Dianat M, Mard SA, Ahangarpour A; Statistical analysis: Ramezani-Aliakbari F, Badavi M; Obtaining financing: Badavi M; Writing of the manuscript: Ramezani-Aliakbari F, Badavi M; Critical revision of the manuscript for intellectual content: Badavi M. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This study was funded by Ahvaz Jundishapur University of Medical Sciences (grant No. APRC-94-25). Study Association This article is part of the thesis of Doctoral submitted by Fatemeh Ramezani-Aliakbari, from Physiology Research Center of Ahvaz Jundishapur University of Medical Sciences. Ethics approval and consent to participate This study was approved by the Ethics Committee on Animal Experiments of the Ahvaz Jundishapur University of Medical Sciences under the protocol number APRC-94-25. 177